Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more

Bullboard (TSX:MDNA)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Comment by windymayor1on Sep 13, 2022 6:06pm

RE:How is this not amazing news ? What am I missing please

Well firstly I would have halted the stock as I think this is material. Then offer a bit more details of the collaberation. what costs are paid by whom etc. Then have a comment from the Merck' ...more  
159
Discussion
Post by TrevorAbeson Sep 13, 2022 5:40pm

MDNA announces clinical collaboration with Merck

https://themarketherald.ca/medicenna-announces-clinical-collaboration-with-merck-to-evaluate-mdna11-in-combination-with-keytruda-pembrolizumab-in-ability-trial-2022-09-13/
96
Comment by windymayor1on Sep 13, 2022 9:43am

RE:Medicenna Announces Clinical Collaboration with Merck

This is big news! MDNA should have halted the stock? Mkt reaction is nil.
80
Discussion
Post by TrevorAbeson Aug 09, 2022 5:14pm

MDNA prices US$20 million public offering

https://themarketherald.ca/medicenna-tsxmdna-prices-us20-million-public-offering-2022-08-09/
184
Post by carolineganon May 06, 2022 4:52pm

Medicenna (TSX:MDNA) drug stimulates anti-cancer response

https://themarketherald.ca/medicenna-announces-new-clinical-data-showing-dose-dependent-stimulation-of-anti-cancer-immune-cells-with-mdna11-in-the-phase-1-2-ability-study-2022-05-02/
191
Post by windymayor1on Jan 26, 2022 2:24pm

PR

Good News. Not sure what the market is waiting for ?!
176
Post by Betteryear2on Jan 26, 2022 8:55am

Peer-Reviewed Publication of Preclinical Data on MDNA11

MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated and induced ...more  
292
Post by HarryGlutenon Nov 17, 2021 8:04am

mdna 52 week high very possible, very soon

$mdna 52 week high of $6.82. If it was done once, it can be done again, esp with big catalyst in less than one month!
314
Post by HarryGlutenon Nov 17, 2021 6:45am

mdna 55 deal

This would be huge: Resesarch Capital Analyst Uddin believes efforts to secure deal for $MDNA 55 prior to start of Phase 3 clinical trial will serve as key catalyst, as he made the assumption of a ...more  
447
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities